The Difference in the Cyclin D1 Expression in Advanced Stage Nasopharyngeal Cancer based on Treatment Response: A Retrospective Cohort Study

Cosphiadi Irawan, Rahmat Cahyanur, Lisnawati Lisnawati, Murdani Abdullah, Reyhan Eddy Yunus

Abstract


Background: nasopharyngeal cancer (NPC) is the most common type of head and neck cancer in Indonesia (28.4%). Reports showed that 18.9% of cases came with advanced stage. Chemotherapy play important role in advanced stage. However, patients with the same stage of the disease may have different treatment response, likely due to the different tumor biological characteristics. Cyclin D1 is a protein involved in the cell cycle, which will stimulate proliferation. This study aimed to examine the proportion of cyclin D1 in NPC and its association with treatment response. Methods: a retrospective cohort study was conducted on advanced NPC patients that underwent chemotherapy at Cipto Mangunkusumo Hospital from 2015 until 2018. Cyclin D1 immunohistochemistry staining was done by antigen retrieval methods using the cyclin D1 NovocastraTM monoclonal antibody. The cyclin D1 expression was evaluated with h-score. Treatment response was reviewed based on the RECIST 1.1 criteria. Results: fifteen subjects (48.4%) had a positive expression of cyclin D1. Higher proportion of cyclin D1 positive was found in responsive group compare with non-responsive group (66.7% vs. 33.3%, p = 0.032). Statistically significant difference in mean h-score was observed between the subjects who responded and those who did not respond (116.24 SD57.80 vs. 77.97 SD45.27, p = 0.048). Conclusion: this study suggests that a higher expression of cyclin D1 is associated with a good treatment response in NPC patients.

Keywords


cyclin D1; nasopharyngeal cancer; treatment response

References


Faisal HH. Analisis kesintasan dan faktor yang berperan pada pasien kanker nasofaring di Departemen THT RSUPN dr. Cipto Mangunkusumo [thesis]. [Jakarta]: Universitas Indonesia; 2017.

Wildeman MA, Fles R, Herdini C, Indrasari RS, Vincent AD, Tjokronagoro M, et al. Primary treatment results of nasopharyngeal carcinoma (NPC) in Yogyakarta, Indonesia. PLoS One. 2013;8(5):e63706.

Ren Y, Qiu H, Yuan Y, et al. Evaluation of 7th edition of AJCC staging system for nasopharyngeal carcinoma. J Cancer. 2017;8(9):1665–72.

Dhingra V, Verma J, Misra V, Srivastav S, Hasan F. Evaluation of cyclin d1 expression in head and neck squamous cell carcinoma. J Clin Diagn Res. 2017;11(2):EC01–EC4.

Gioacchini FM, Alicandri-Ciufelli M, Kaleci S, Magliulo G, Presutti L, Re M. The prognostic value of cyclin d1 expression in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2016;273(4):801–9.

Li Y, Barbash O, DIehl JA. Regulation of the cell cycle. In: Mendelsohn J, Gray JW, Howley PM, Israel MA, Thompson CB, editors. The molecular basis of cancer. Philadelphia: Elsevier; 2015. p. 165–78.

Akervall J, Brun E, Dictor M, Wennerberg J. Cyclin d1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report. Acta Oncol. 2001;40(4):505–11.

Seiler R, Thalmann GN, Rotzer D, Perren A, Fleischmann A. Ccnd1/cyclind1 status in metastasizing bladder cancer: A prognosticator and predictor of chemotherapeutic response. Mod Pathol. 2014;27(1):87–95.

Ngo BT, Felthaus J, Hein M, et al. Monitoring bortezomib therapy in multiple myeloma: Screening of cyclin d1, d2, and d3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome. Leuk Lymphoma. 2010;51(9):1632–42.

Noel EE, Yeste-Velasco M, Mao X, et al. The association of ccnd1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol. 2010;176(6):2607–15.

Biliran H, Jr., Wang Y, Banerjee S, et al. Overexpression of cyclin d1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res. 2005;11(16):6075–86.

American Joint Committee on Cancer. 8th edition implementation project 2018 [Internet]. [cited 2018 15 October]. Available from: https://cancerstaging.org/8thEdImplementation/Pages/default.aspx.

Recondo G, Armand JP, Tellez-Bernal E, et al. Recurrent and/or metastatic head and neck squamous cell carcinoma: A clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope. 1991;101(5):494–501.

Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365(9476):2041–54.

Adham M, Kurniawan AN, Muhtadi AI, et al. Nasopharyngeal carcinoma in indonesia: Epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012;31(4):185–96.

Jayalie VF, Paramitha MS, Jessica, et al. Profile of nasopharyngeal carcinoma in Cipto Mangunkusumo National Hospital, 2010. eJKI. 2016;4(3):156–62.

Shen L, Dong J, Li S, et al. M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma. Oncologist. 2015;20(3):291–8.

Chan J, Pilch B, Kuo T, Wenig B, Lee A. Tumours of the nasopharynx. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World health organization pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005. p. 83–97.

Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: Randomised, non-inferiority, open trial. Eur J Cancer. 2007;43(9):1399–406.

Kua VF, Ismail F, Phua VCE, Aslan NM. Carboplatin/5-fluorouracil as an alternative to cisplatin/5-fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 2013;14(2):1121–6.

Hwang CF, Cho CL, Huang CC, et al. Loss of cyclin d1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy. Ann Oncol. 2002;13(8):1246–51.

Jirawatnotai S, Sittithumcharee G. Paradoxical roles of cyclin d1 in DNA stability. DNA Repair (Amst). 2016;42:56–62.

Qie S, Diehl JA. Cyclin d1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl). 2016;94(12):1313–26.

Xu Y, Shi Y, Yuan Q, et al. Epstein-barr virus encoded lmp1 regulates cyclin d1 promoter activity by nuclear eGFR and STAT3 in CNE1 cells. J Exp Clin Cancer Res. 2013;32:90.

Hsu C-L, Lui K-W, Chi L-M, et al. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor palbociclib as a novel candidate drug for nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2018;37(1):233.

Jiao X-D, Liu K, Qin B-D, et al. Palbociclib for the treatment of metastatic nasopharyngeal carcinoma with cdk4 amplification: A case report. JCO Precis Oncol. 2019;(3):1–4.

Akervall J, Kurnit DM, Adams M, et al. Overexpression of cyclin d1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck. Acta Otolaryngol. 2004;124(7):851–7.

Sun Y, Luo D, Liao DJ. Cyclind1 protein plays different roles in modulating chemoresponses in mcf7 and mda-mb231 cells. J Carcinog. 2012;11:12.

Richardson C, Stark JM, Ommundsen M, Jasin M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene. 2004;23(2):546–53.

Myklebust MP, Li Z, Tran TH, et al. Expression of cyclin d1a and d1b as predictive factors for treatment response in colorectal cancer. Br J Cancer. 2012;107(10):1684–91.


Full Text: PDF

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Acta Medica Indonesiana